CLLS

Cellectis
CLLS

$2.42
7.66%
 

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Employees: 216

0
Funds holding %
of 6,689 funds
Analysts bullish %
0
News positive %
of 7 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

0.04% more ownership

Funds ownership: 13.68% [Q4 2023] → 13.73% (+0.04%) [Q1 2024]

12% less funds holding

Funds holding: 34 [Q4 2023] → 30 (-4) [Q1 2024]

14% less capital invested

Capital invested by funds: $30.2M [Q4 2023] → $26.1M (-$4.14M) [Q1 2024]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $81.9K

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
148%
upside
Avg. target
$8
231%
upside
High target
$10
313%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Hartaj Singh
313%upside
$10
Outperform
Maintained
12 Jun 2024
JMP Securities
Silvan Tuerkcan
148%upside
$6
Market Outperform
Reiterated
31 May 2024

Financial journalist opinion

Based on 7 articles about CLLS published over the past 30 days